Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986165 in Lupus Nephritis
NCT03943147Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of deucravacitinib in lupus nephritis (LN), sponsored by Bristol Myers Squibb. Started Jul 2019; status: terminated.
02
Drugs
deucravacitinib
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT03943147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943147.